Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT03285997
Other study ID # GC3110A_IF_P3
Secondary ID
Status Not yet recruiting
Phase Phase 3
First received September 13, 2017
Last updated September 15, 2017
Start date September 30, 2017
Est. completion date August 31, 2018

Study information

Verified date September 2017
Source Green Cross Corporation
Contact Han-A Cha
Phone +82-260-1936
Email hacha@greencross.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

If study subject's legal guardians who decide voluntarily to participate the clinical trial, and sign the Informed Consent Formed, study subjects eligible for participating this trial protocol were assigned to test group or control group with the ratio of 4:1 and receiving the test or control drug 1 time or 2 times.


Description:

1. Part 1 If study subject's legal guardians who decide voluntarily to participate the clinical trial, and sign the Informed Consent Form, study subjects eligible for participating this trial protocol were assigned to test group and receiving the test drug 1 time or 2 times.

2. Part 2 If study subject's legal guardians who decide voluntarily to participate the clinical trial, and sign the Informed Consent Formed, study subjects eligible for participating this trial protocol were assigned to test group or control group with the ratio of 4:1 and receiving the test or control drug 1 time or 2 times.

The investigator will evaluate the efficacy and safety of the test product while clinical trial.

Blood samples will be collected at visit 1 and visit 5 for immunogenicity evaluation. The study subject and their legal guardians will be educated to daily record AEs after vaccination on the patient diary to evaluate the safety.

At visit1, blood samples will be collected from randomized study subjects and investigational drug will be intramuscularly injected. However, those who had not been vaccinated with influenza vaccine, will re-visit and have the 2nd vaccination, 4~5 weeks after the 1st vaccination.

After 4~5 weeks since last vaccination, study subjects will visit and blood sample will be collected. And the serious adverse events occurred during 180 days after the final vaccination will be checked through the telephone visit.

The study subjects with 1 dose of vaccine will have 4 visits including Visit 1~2 and Visit 5~6. The study subjects with 2 dose of vaccine will have 6 visits including Visit 3~4.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 260
Est. completion date August 31, 2018
Est. primary completion date May 31, 2018
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 6 Months to 35 Months
Eligibility Inclusion Criteria:

1. Healthy infants aged 6 month to 3 years.

2. Study subject was born at full term pregnancy(37 week)

3. Study subject who understand the details of this clinical trial, decide voluntarily to participate the trial, and signed the Informed Consent Form

Exclusion Criteria:

1. Those with a history of allergic reaction to eggs or chicken, the vaccine components

2. Those who had been ad ministered the influenza vaccine 6 months prior to the study drug vaccination

3. Those with immunologic impairment including immune deficiency disorders or family history about it.

4. Those with a history of Guillain-Barre syndrome

5. Those with a history of Down's syndrome or cytogenetic disorders

6. Those who would be ineligible to participate the study as follows: serious chronic disease

7. Hemophilia patients at risk of serious bleeding with intramuscular injection or those receiving anticoagulant therapy

8. Those who have active infection or who have fever higher than 38.0? within 72 hours prior to the dosing of study drug

9. Those who had been vaccinated with another vaccine within 28 days prior to the dosing of study drug or had a scheduled vaccination during the clinical trial period

10. Those who had received an immunosuppressant, immunity-modifying drug within 3 months prior to the dosing of study drug

11. Those who had received immunoglobulin or a blood-derived product within 3 months prior to the dosing of study drug or is scheduled to receive those products during the study period

12. Those who had taken antipyretic/analgesic/nonsteroidal antiinflammatory drugs within 4 hours prior to the dosing of study drug

13. Study subject who had participated in other clinical trial within 28 days prior to the study vaccination

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
GC3110A
A single 0.5mL dose intramuscular injection
GCFLU Pre-filled syringe inj.
A single 0.25mL dose intramuscular injection

Locations

Country Name City State
Korea, Republic of The Catholic Univ.of Korea Seoul St.Mary's Hospital Seoul

Sponsors (1)

Lead Sponsor Collaborator
Green Cross Corporation

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type Measure Description Time frame Safety issue
Primary Seroconversion rate for HI antibody after final injection the percentage of study subjects with a pre-vaccination (Day 0) HI titer<1:10 and post-vaccination (Day 28) HI antibody titer=1:40(Case1), or the percentage of study subjects with a pre-vaccination HI antibody titer=1:10 and a minimum four-fold rise in post-vaccination HI antibody titer(Case 2) Post-vaccination (Day 28 or 56)
Primary Seroprotection rate for HI antibody after final injection Post-vaccination (Day 28 or 56)
Secondary GMT GMT(Geometric Mean Titer) of HI antibody titer before vaccination(Day 0) and after vaccination (Day 28) Post-vaccination (Day 28 or 56)
Secondary GMR GMR(Geometric Mean Ratio) of HI antibody titer before vaccination(Day 0) and after vaccination (Day 28) Post-vaccination (Day 28 or 56)
See also
  Status Clinical Trial Phase
Recruiting NCT05996549 - Cost-effectiveness of the Influenza Vaccination Phase 4
Completed NCT04546854 - Influenza 2020/2021 N/A
Completed NCT05157425 - Effect of a Multi-strain Probiotic Formulation on Immune Response to Influenza Vaccination N/A
Completed NCT01687517 - Efficacy and Safety of Influenza Vaccine During Sarcoidosis Phase 3
Completed NCT01180699 - Intradermal Versus Intramuscular Trivalent Influenza Vaccine in Adult Solid Organ Transplant Recipients N/A
Completed NCT00760175 - Intradermal Versus Intramuscular Trivalent Influenza Vaccine in Adult Lung Transplant Recipients N/A
Completed NCT00542776 - Impact of Immunosuppression in IBD Patients on Response to Influenza Vaccine N/A
Completed NCT06304038 - Cost-consequence Analysis of Influenza Vaccination in a Teaching Hospital in Rome
Recruiting NCT04086628 - Influenza Vaccine in Children With Asthma
Completed NCT02960815 - Imiquimod and Influenza Vaccine for Immunocompromised Patients Phase 2
Completed NCT00828555 - Effectiveness of a Vaccination Program in the Community Ob/Gyn Setting N/A
Completed NCT04230343 - Limits of the Social Benefit Motive Among High-risk Patients: a Field Experiment on Influenza Vaccination Behaviour N/A
Recruiting NCT03399357 - Evaluation of Metabolic Predictors of Influenza Vaccine Immune Response in the Singapore Elderly Population - the DYNAMIC Trial N/A
Completed NCT02153671 - Immunogenicity of H5N1 Vaccine Following H5N2 Phase 2
Completed NCT00461981 - A Phase 2 Study to Evaluate Immune Responses of FluMist® Phase 2
Recruiting NCT05070494 - Efficacy of Different Doses of Influenza Vaccine in Chronic Hemodialysis Patients Phase 4
Completed NCT04785794 - Safety and Immunogenicity of the Sing2016 M2SR H3N2 Monovalent Influenza Vaccine in Adults Ages 50 to 85 Years Old Phase 1
Completed NCT05163847 - Safety and Immunogenicity of Cam2020 M2SR H3N2 Monovalent Influenza Vaccine Alone or With Licensed IIV in Older Adults Phase 1
Not yet recruiting NCT04355806 - Impact of Inactivated Trivalent Influenza Vaccine on NSCLC Patients Receiving PD-1 / PD-L1 Inhibitors
Completed NCT01368796 - Comparison of 4 Influenza Vaccines in Seniors Phase 4